ClinicalTrials.gov
ClinicalTrials.gov Menu

Faslodex International Observational Non-Interventional Study in Advanced Breast Cancer (BC) (FIONA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00880711
Recruitment Status : Completed
First Posted : April 14, 2009
Last Update Posted : November 30, 2011
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
The purpose is to collect real life data on the use of fulvestrant in normal clinical practice in Austria and document the clinical benefit of fulvestrant treatment.

Condition or disease
Breast Cancer

Study Type : Observational
Actual Enrollment : 57 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Faslodex International Observational Non-Interventional Study in Advanced Breast Cancer
Study Start Date : April 2009
Actual Primary Completion Date : September 2010
Actual Study Completion Date : December 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Fulvestrant

Group/Cohort
1
Patient with advanced BC, already receiving Faslodex therapy



Primary Outcome Measures :
  1. Clinical Benefit, defined as the development of at least one of the following stages and holding on for at least 6 month: Complete response, partial response or stable disease [ Time Frame: Baseline, after 3, 6, 9 month ]

Secondary Outcome Measures :
  1. Tolerability [ Time Frame: After 3, 6, 9 month (as per usual clinical practice) ]
  2. Quality of Life [ Time Frame: Baseline, after 3, 6, 9 month (as per usual clinical practice) ]
  3. Performance status (Karnofsky Index) [ Time Frame: Baseline, after 3, 6, 9 month (as per usual clinical practice) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Hospitals, office based specialists
Criteria

Inclusion Criteria:

  • Postmenopausal women with hormone receptor-positive locally advanced or metastatic breast cancer
  • Ability to read and write and complete questionnaires
  • Provision of written informed consent
  • Patients who already received a prescription for fulvestrant

Exclusion Criteria:

  • A subject who does not fulfil all the above mentioned inclusion criteria is not allowed to participate in this NIS

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00880711


Locations
Austria
Research Site
Graz, Austria
Research Site
Innsbruck, Austria
Research Site
Klagenfurt, Austria
Research Site
Leoben, Austria
Research Site
Linz, Austria
Research Site
Oberpullendorf, Austria
Research Site
Rankweil, Austria
Research Site
Rottenmann, Austria
Research Site
Salzburg, Austria
Research Site
St. Veit, Austria
Research Site
Steyr, Austria
Research Site
Vienna, Austria
Research Site
Wr. Neustadt, Austria
Sponsors and Collaborators
AstraZeneca
Investigators
Study Chair: Guenther Steger, Univ Prof. Dr. Medical University of Vienna

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00880711     History of Changes
Other Study ID Numbers: NIS-OAT-FAS-2009/1
First Posted: April 14, 2009    Key Record Dates
Last Update Posted: November 30, 2011
Last Verified: November 2011

Keywords provided by AstraZeneca:
Fiona
Faslodex
Advanced Breast Cancer
Real life data
Collect real life data in clinical practice across Austria

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Fulvestrant
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Estrogen Receptor Antagonists
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs